Powered by

Soligenix to Present at the RHK Capital 2019 Disruptive Growth Conference

Aug 29, 2019 - PR Newswire
Event Announcements

PR Newswire

Soligenix, Inc. (Nasdaq: SNGX) (Soligenix or the Company), a late-stage biopharmaceutical company focused on developing and commercializing products to treat rare diseases where there is an unmet medical need, announced today that its President and Chief Executive Officer, Christopher J. Schaber, PhD, will deliver a corporate presentation to review upcoming potential milestones for the Company's two pivotal phase 3 clinical programs in cutaneous T-cell lymphoma and oral mucosit...